Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cidara Therapeutics Inc chart...

About the Company

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.

CEO

Jeffrey Stein

Exchange

NASDAQ

Website

http://www.cidara.com/

$54M

Total Revenue

81

Employees

$62M

Market Capitalization

-2.22

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CDTX News

Cidara Therapeutics files patent for synthesis of conjugates for treating viral infections

6d ago, source: Pharmaceutical Technology

Discover Cidara Therapeutics' innovative patent for synthesizing viral infection treatments. Learn about conjugates with neuraminidase inhibitors and Fc domain monomers.

Cidara Therapeutics, Inc.

9d ago, source: CNN

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and ...

Larimar: Q4 Earnings Snapshot

4d ago, source:

BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $13 million in its fourth quarter. On a per-share basis, the Bala Cynwyd, ...

Lava gets $7M from Pfizer as trial for cancer drug advances

13d ago, source: Seeking Alpha on MSN

LAVA Therapeutics (NASDAQ:LVTX) announced Tuesday that Pfizer (PFE) had reached a key milestone in its clinical program for ...

Applied Molecular Transport files patent for oral delivery of therapeutic payload using carrier-payload complex

6d ago, source: Pharmaceutical Technology

Discover the innovative patent by Applied Molecular Transport Inc. for efficient delivery of therapeutic payloads using carrier-payload complexes derived from Cholix polypeptides. Explore the ...

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

4d ago, source:

Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in ...

Buy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug Nomlabofusp

3d ago, source:

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Larimar Therapeutics (LRMR – Research Report), with a price ...

Larimar Therapeutics to Present at Global Biopharma Conference in Miami

7d ago, source: MyChesCo on MSN

Larimar Therapeutics, Inc. (Nasdaq: LRMR), a biotechnology company specializing in the development of gene therapies, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...